These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31914156)

  • 1. Leadership for success in transforming medical abortion policy in Canada.
    Dineley B; Munro S; Norman WV
    PLoS One; 2020; 15(1):e0227216. PubMed ID: 31914156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacist dispensing of the abortion pill in Canada: Diffusion of Innovation meets integrated knowledge translation.
    Munro S; Wahl K; Soon JA; Guilbert E; Wilcox ES; Leduc-Robert G; Ansari N; Devane C; Norman WV
    Implement Sci; 2021 Aug; 16(1):76. PubMed ID: 34344393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could implementation of mifepristone address Canada's urban-rural abortion access disparity: a mixed-methods implementation study protocol.
    Norman WV; Munro S; Brooks M; Devane C; Guilbert E; Renner R; Kendall T; Soon JA; Waddington A; Wagner MS; Dunn S
    BMJ Open; 2019 Apr; 9(4):e028443. PubMed ID: 31005943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication abortion in Canada: a right-to-health perspective.
    Erdman JN; Grenon A; Harrison-Wilson L
    Am J Public Health; 2008 Oct; 98(10):1764-9. PubMed ID: 18703434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancing Reproductive Health through Policy-Engaged Research in Abortion Care.
    Munro SB; Dunn S; Guilbert ER; Norman WV
    Semin Reprod Med; 2022 Nov; 40(5-06):268-276. PubMed ID: 36746159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Availability and acceptability of medical abortion in Nepal: health care providers' perspectives.
    Tamang A; Tamang J
    Reprod Health Matters; 2005 Nov; 13(26):110-9. PubMed ID: 16291492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives Among Canadian Physicians on Factors Influencing Implementation of Mifepristone Medical Abortion: A National Qualitative Study.
    Munro S; Guilbert E; Wagner MS; Wilcox ES; Devane C; Dunn S; Brooks M; Soon JA; Mills M; Leduc-Robert G; Wahl K; Zannier E; Norman WV
    Ann Fam Med; 2020 Sep; 18(5):413-421. PubMed ID: 32928757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Canadian women's knowledge of and interest in mifepristone: results from a national qualitative study with abortion patients.
    Vogel KI; LaRoche KJ; El-Haddad J; Chaumont A; Foster AM
    Contraception; 2016 Aug; 94(2):137-42. PubMed ID: 27125893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Has mifepristone medical abortion expanded abortion access in New Mexico? A survey of OB-GYN and Family Medicine physicians.
    Espey E; Leeman L; Ogburn T; Skipper B; Eyman C; North M
    Contraception; 2011 Aug; 84(2):178-83. PubMed ID: 21757060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical abortion still not available in most countries.
    Ferriman A
    BMJ; 1999 Oct; 319(7217):1091. PubMed ID: 10531093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services.
    Haldane J
    BJOG; 2008 Nov; 115(12):1587-8; author reply 1588-9. PubMed ID: 19054856
    [No Abstract]   [Full Text] [Related]  

  • 12. Mifepristone (RU486) in Australian pharmacies: the ethical and practical challenges.
    Lee RY; Moles R; Chaar B
    Contraception; 2015 Jan; 91(1):25-30. PubMed ID: 25248673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to Reevaluate U.S. Mifepristone Restrictions.
    Henney JE; Gayle HD
    N Engl J Med; 2019 Aug; 381(7):597-598. PubMed ID: 31242357
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA considering restricted access to "abortion pill".
    Sibbald B
    CMAJ; 2000 Sep; 163(5):586. PubMed ID: 11006770
    [No Abstract]   [Full Text] [Related]  

  • 15. Canadian Contraception Consensus (Part 2 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
    J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Judicial interference with mifepristone.
    Hamburg M; Sharfstein J
    Science; 2023 Apr; 380(6642):223. PubMed ID: 37053463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services.
    Gomperts R; Kleiverda G; Gemzell K; Davies S; Jelinska K
    BJOG; 2008 Nov; 115(12):1578-9. PubMed ID: 19035995
    [No Abstract]   [Full Text] [Related]  

  • 18. Research to Action: an evaluation.
    Murphy GT; Alder R; MacKenzie A; Cook A; Maddalena V
    Nurs Leadersh (Tor Ont); 2012 Mar; 25 Spec No 2012():21-32. PubMed ID: 22398474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Availability of medical abortion pills and the role of chemists: a study from Bihar and Jharkhand, India.
    Ganatra B; Manning V; Pallipamulla SP
    Reprod Health Matters; 2005 Nov; 13(26):65-74. PubMed ID: 16291487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing abortion coverage in nurse practitioner programs in Canada: a national survey of program directors.
    Sheinfeld L; Arnott G; El-Haddad J; Foster AM
    Contraception; 2016 Nov; 94(5):483-488. PubMed ID: 27374736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.